Work

Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment

Year: 2024

Type: article

Study design: Clinical Trial

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2024.02.010

Authors: Jazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, Ahmed El-Zawahry, James Peabody, Tiffany Pearce, Nicole Adams, Mustafa Deebajah, Danuta Dynda, Kara Babaian, Jane Crabtree, Kristin Delfino, Kevin McVary, Kathy Robinson, Krishna Rao, Shaheen Alanee

Institutions: Southern Illinois University Carbondale, SIU Medicine, Aurora Health Care, University of Toledo Medical Center, Henry Ford Health, Loyola University Medical Center, Loyola Medicine, Detroit Medical Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Merck, Henry Ford Health System

OpenAlex ID: W4392247227

FWCI: 2.714

Cites: 13

Cited by: 7

Related to: 10